Background: Chronic cancer-related fatigue is difficult to manage in breast cancer survivors. The tango trial showed that a six-week tango Argentino program was effective in reducing fatigue and improving quality of life, and here we investigated the sustainability of this tango program for breast cancer survivors. Methods: Stage I–III breast cancer survivors with increased fatigue symptoms were analyzed. The fifty participants in the tango trial were compared with a control cohort (n= 108) who did not participate in the tango program. Using the European Organization for Research and Treatment of Cancer Questionnaire C30 (EORTC-QLQ-C30) and the German version of the cancer fatigue scale (CFS-D) self-reported quality of life parameters were assessed and longitudinal changes, correlations, and association factors were calculated. Results: Significant improvements in fatigue (p= 0.006), physical functioning (p= 0.01), and diarrhea (p= 0.04) persisted in the 50 Tango participants at 6 months, but not in the control cohort. Twelve months after joining the tango program, increased fatigue was associated with reduced sporting activities (p= 0.0005), but this was not the case for tango dancing. Conclusions: The present results suggest that tango may be appropriate as a component of early supportive and follow-up care programs, to promote health-related quality of life and physical activity and also eventually to improve long-term clinical outcomes of breast cancer survivors. Trial registration: Trial registration numbers DRKS00013335 on 27 November 2017 and DRKS00021601 on 21 August 2020 retrospectively registered.
背景：慢性癌症相关疲劳在乳腺癌幸存者中难以管理。探戈试验表明，为期六周的阿根廷探戈项目能有效减轻疲劳并改善生活质量，本研究旨在探讨该探戈项目对乳腺癌幸存者疲劳改善效果的持续性。方法：对疲劳症状加重的I-III期乳腺癌幸存者进行分析。将参与探戈试验的50名受试者与未参与探戈项目的对照组队列（n=108）进行比较。采用欧洲癌症研究与治疗组织生活质量核心问卷（EORTC-QLQ-C30）及德文版癌症疲劳量表（CFS-D）评估自我报告的生活质量参数，并计算纵向变化、相关性及关联因素。结果：50名探戈参与者在6个月时仍持续表现出疲劳（p=0.006）、躯体功能（p=0.01）和腹泻症状（p=0.04）的显著改善，而对照组未出现类似改善。参与探戈项目12个月后，疲劳加重与体育活动减少相关（p=0.0005），但探戈舞蹈活动未呈现此关联。结论：本研究结果表明，探戈可作为早期支持性和随访护理计划的组成部分，有助于提升健康相关生活质量和身体活动水平，并可能最终改善乳腺癌幸存者的长期临床结局。试验注册：追溯性注册号DRKS00013335（2017年11月27日）和DRKS00021601（2020年8月21日）。
肿瘤(癌症)患者之家